DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

Analysts at StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Monday. The firm set a “sell” rating on the stock.

DBVT has been the subject of several other reports. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of DBV Technologies in a report on Tuesday, August 1st. JMP Securities restated a “market outperform” rating and set a $4.00 price objective on shares of DBV Technologies in a research note on Tuesday, August 1st. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $7.00.

DBV Technologies Trading Down 1.3 %

DBVT traded down $0.02 during midday trading on Monday, reaching $1.53. The company’s stock had a trading volume of 61,731 shares, compared to its average volume of 131,159. DBV Technologies has a 1 year low of $1.08 and a 1 year high of $2.43. The stock’s 50-day moving average is $1.61 and its 200-day moving average is $1.70. The firm has a market capitalization of $294.53 million, a price-to-earnings ratio of -2.73 and a beta of 1.17.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings results on Monday, July 31st. The company reported ($0.13) EPS for the quarter, hitting analysts’ consensus estimates of ($0.13). The company had revenue of $2.29 million during the quarter, compared to the consensus estimate of $1.00 million. As a group, equities research analysts forecast that DBV Technologies will post -0.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

Large investors have recently bought and sold shares of the business. Point72 Asset Management L.P. bought a new position in DBV Technologies during the second quarter valued at approximately $5,914,000. Citadel Advisors LLC bought a new position in shares of DBV Technologies during the 2nd quarter valued at $55,000. BlackRock Inc. boosted its stake in shares of DBV Technologies by 4.6% in the 2nd quarter. BlackRock Inc. now owns 1,017,670 shares of the company’s stock worth $1,934,000 after buying an additional 44,414 shares during the last quarter. Optiver Holding B.V. bought a new stake in shares of DBV Technologies in the second quarter worth $75,000. Finally, BNP Paribas Arbitrage SNC increased its position in DBV Technologies by 74.2% during the second quarter. BNP Paribas Arbitrage SNC now owns 39,034 shares of the company’s stock valued at $74,000 after acquiring an additional 16,626 shares during the last quarter. 23.90% of the stock is currently owned by institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis.